BeyondSpring (BYSI) Profit After Tax (2016 - 2026)
BeyondSpring (BYSI) posted Profit After Tax of -$7.1 million for Q1 2026, down 12.04% sequentially from -$6.3 million in Q4 2025, and down 258.59% YoY from $4.5 million in Q1 2025.
BeyondSpring (BYSI) Profit After Tax (2016 - 2026) Analysis & Trends
BeyondSpring has reported Profit After Tax for 9 years, with the latest figure at -$7.1 million in Q1 2026.
- Quarterly Profit After Tax fell 258.59% year-over-year to -$7.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$23.2 million (down 144.24% YoY) and the FY2025 annual result came in at -$15.5 million, up 7.32% from the prior year.
- Profit After Tax eased to -$7.1 million in Q1 2026 per BYSI's latest filing, from -$6.3 million in the prior quarter.
- Over five years, Profit After Tax peaked at $4.5 million in Q1 2025 and troughed at -$7.1 million in Q1 2026.
- A 3-year average of -$4.0 million and a median of -$4.6 million in 2025 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2025 and 2026: Profit After Tax jumped 236.16% in 2025, then slumped 258.59% in 2026.
- Over 3 years, Profit After Tax stood at -$4.4 million in 2024, then tumbled by 43.44% to -$6.3 million in 2025, then slipped by 12.04% to -$7.1 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$7.1 million, -$6.3 million, and -$5.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | BeyondSpring | 29.85 Mn | 29.85 Mn | - | -6.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.24 Mn |
| Mar 31, 2026 | -7.10 Mn |
| Dec 31, 2025 | -6.34 Mn |
| Sep 30, 2025 | -5.13 Mn |
| Jun 30, 2025 | -4.65 Mn |
| Mar 31, 2025 | 4.48 Mn |
| Dec 31, 2024 | -4.42 Mn |
| Sep 30, 2024 | -5.47 Mn |
| Jun 30, 2024 | -4.09 Mn |
| Mar 31, 2024 | -3.29 Mn |
| Dec 31, 2021 | -10.90 Mn |
| Sep 30, 2021 | -20.18 Mn |
| Jun 30, 2021 | -20.04 Mn |
| Mar 31, 2021 | -17.44 Mn |
| Dec 31, 2020 | -18.68 Mn |
| Sep 30, 2020 | -15.46 Mn |
| Jun 30, 2020 | -13.60 Mn |
| Mar 31, 2020 | -16.66 Mn |
| Dec 31, 2019 | -15.06 Mn |
| Sep 30, 2019 | -9.82 Mn |